1. Origin and impact of multifocal growth in sporadic vs. hereditary medullary thyroid cancer.
- Author
-
Machens A, Lorenz K, Weber F, and Dralle H
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Carcinoma, Medullary genetics, Carcinoma, Medullary pathology, Carcinoma, Medullary congenital, Multiple Endocrine Neoplasia Type 2a genetics, Multiple Endocrine Neoplasia Type 2a pathology, Aged, Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine genetics, Thyroidectomy, Adolescent, Neoplasm Invasiveness, Disease Progression, Young Adult, Thyroid Neoplasms pathology, Thyroid Neoplasms genetics, Proto-Oncogene Proteins c-ret genetics, Calcitonin blood, Lymphatic Metastasis
- Abstract
Multifocal growth is characteristic of hereditary medullary thyroid cancer (MTC), whereas origin and impact of multifocal growth is enigmatic for sporadic MTC. To address this, 460 RET-negative patients with sporadic MTC, stratified by 1 (93.3 %), 2 (5.7 %) and 3 (1.1 %) thyroid tumor foci, were compared with 219 RET-positive patients with hereditary MTC, stratified by 1 (38.4 %), 2 (45.7 %), 3 (6.4 %), 4 (6.8 %) and ≥5 (2.7 %) thyroid tumor foci. For sporadic MTC, significant associations were identified with bilateral thyroid lobe involvement, microscopic lymphatic invasion, extrathyroid extension, node and distant metastases, number of node metastases, preoperative basal calcitonin level, and decreasing biochemical cure. For hereditary MTC, significant associations were limited to bilateral thyroid lobe involvement, largest thyroid tumor diameter, and preoperative basal calcitonin level. In sporadic MTC, multifocal growth is due to lymphatic invasion with frequent node metastases, whereas in hereditary MTC, it reflects malignant progression from C-cell hyperplasia to cancer., Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported., (Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF